Dechra Pharmaceuticals : Director/PDMR Shareholdings

18 September 2019

Dechra Pharmaceuticals PLC

Notification of Transactions by Persons Discharging Managerial Responsibilities

On 17 September 2019, Dechra Pharmaceuticals PLC was notified by Directors of the Company and Persons Discharging Managerial Responsibilities that they had completed the sale of part of their beneficial interest in Dechra.

Ian Page, Executive Director and Tony Rice, Non-Executive Chairman, have sold 200,000 ordinary shares and 20,000 ordinary shares respectively in the Companyto satisfy long term personal financial planning considerations and widen their investment portfolios. The shares have been placed in the market with investors. Following these transactions, Ian Page will continue to retain a beneficial holding of 586,650 which represents 0.571% and Tony Rice, 20,000 representing 0.019% of the current issued share capital in the Company.

The Notification of Dealing Forms set out below are provided in accordance with Article 19.3 of MAR.

Notification of Dealing Form:

1.	Details of the Person Discharging Managerial Responsibility ('PDMR')/person closely associated with them ('PCA')
a)	Name	Ian Page
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Sale of Shares
c)	Price(s) and volumes(s)	Price(s) £29.1695	Volume(s) 200,000
d)	Aggregated information -Aggregate volume - Price - Total	200,000 £29.1695 £5,833,900
e)	Date of the transaction	17 September 2019
f)	Place of the transaction	London Stock Exchange

Notification of Dealing Form:

1.	Details of the Person Discharging Managerial Responsibility ('PDMR')/person closely associated with them ('PCA')
a)	Name	Tony Rice
2.	Reason for the notification
a)	Position/status	Director
b)	Initial notification/amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Dechra Pharmaceuticals PLC
b)	LEI code	213800J4UVB5OWG8VX82
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 1 pence each ISIN: GB0009633180
b)	Nature of the transaction	Sale of Shares
c)	Price(s) and volumes(s)	Price(s) £29.09968	Volume(s) 20,000
d)	Aggregated information -Aggregate volume - Price - Total	20,000 £29.09968 £581,993.60
e)	Date of the transaction	17 September 2019
f)	Place of the transaction	London Stock Exchange

Enquiries:
Dechra Pharmaceuticals PLC
Ishbel Macpherson, Senior Independent Director	Office: [phone]
Ian Page, Chief Executive Officer	Office: [phone]
Paul Sandland, Acting Chief Financial Officer e-mail:[e-mail]	Office: [phone]
TooleyStreet Communications Ltd
Fiona Tooley, Director e-mail:[e-mail]	Office: [phone] Mobile: [phone]

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit:www.dechra.com

Trademarks

Dechra and the Dechra 'D' logo are registered trademarks of Dechra Pharmaceuticals PLC.